Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant encephalitis B virus and application thereof

A technology for recombining viruses and proteins, applied in the fields of application, viral peptides, antiviral agents, etc., can solve the problem of no effective treatment for Japanese encephalitis, and achieve good application prospects, low possibility, and high safety Effect

Active Publication Date: 2013-03-13
MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there is no effective treatment for Japanese encephalitis, and it can only be prevented by vaccination

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant encephalitis B virus and application thereof
  • Recombinant encephalitis B virus and application thereof
  • Recombinant encephalitis B virus and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1, construction and identification of Japanese encephalitis virus E218A

[0035] The purpose of this example is to construct a methyltransferase-deficient recombinant Japanese encephalitis virus (also known as Japanese encephalitis virus E218A, represented by E218A). The schematic diagram of the cDNA structure corresponding to the full-length RNA of the wild-type Japanese encephalitis virus (virulent strain, represented by WT) and the mutation site are shown in figure 1 .

[0036] The cDNA sequence corresponding to the full-length RNA of the wild-type Japanese encephalitis virus (virulent strain) is shown in sequence 1 of the sequence table, from the 1st to the 95th nucleotide of the 5' end is the 5'UTR, the 96th -476th nucleotide is the coding gene of capsid protein C (C), the 477th-2477th nucleotide is the coding gene of prM-E protein (prM-E), and the 2478th-3722nd nucleotide is Nucleotides 3723-4607 of the gene encoding the nonstructural protein NS1 (NS1...

Embodiment 2

[0090] Embodiment 2, the infection rate of Japanese encephalitis virus to BHK-21 cell

[0091] The transcript RNA obtained in step 3 of Example 1 and the transcript RNA obtained in step 2 of 2 were determined as follows:

[0092] 1. Infect monolayer BHK-21 cells with transcript RNA, collect cells at 24, 48, and 72 hours after infection, resuspend in DMEM medium containing 10% FBS, spread on glass slides, and store at 37°C, 5% CO 2 After culturing under the same conditions for 8-12 hours, the antigen sheet was obtained. The antigen sheet was fixed in acetone at -20°C for 30-60 minutes, dried and placed in a refrigerator at -20°C to be sealed for use.

[0093] 2. Using the Japanese encephalitis virus envelope E protein polyclonal antibody (purchased from abcam company, the product catalog number is ab41671), the virus-specific protein in BHK-21 cells was detected by indirect immunofluorescence. The method is as follows: Dilute the antibody in an appropriate ratio, incubate with...

Embodiment 3

[0095] Embodiment 3, the plaque characteristic of Japanese encephalitis virus

[0096] The Japanese encephalitis virus E218A seed liquid prepared in Example 1 and the wild type Japanese encephalitis virus (virulent strain) seed liquid were detected as follows:

[0097] Set the titer to 1 x 10 8 The Japanese encephalitis virus E218A seed solution of PFU / mL was serially diluted 10 times with DMEM medium containing 2% FBS (the dilution was 10 -1 、10 -2 、10 -3 、10 -4 , 10 -5 、10 -6 and 10 -7 ). Set the titer to 4 x 10 8 PFU / mL (virulent strain) of wild-type Japanese encephalitis virus (virulent strain) seed solution was diluted 10-fold with DMEM medium containing 2% FBS (the dilution was 10 in sequence) -1 、10 -2 、10 -3 、10 -4 、10 -5 、10 -6 and 10 -7 ). Inoculate 500 μl / well of each dilution on a monolayer of BHK-21 cells spread on a 6-well plate at 37°C, 5% CO 2 Let stand for 1-2 hours under the conditions, discard the culture supernatant, add agar cover (that is...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a recombinant encephalitis B virus and application thereof. The invention provides a protein which is obtained by mutating a 218th-site amino acid residue on an N terminal of the protein shown as a sequence 3 of a sequence table from a polar amino acid to a non-polar amino acid. The invention also discloses a gene coding the protein, a recombinant expression vector containing the gene, an expression cassette, a transgenic cell line, and a recombinant virus or recombinant bacterium. The invention also discloses an encephalitis B virus vaccine of which the active ingredient is the recombinant virus. The recombinant encephalitis B virus provided by the invention can be used as the encephalitis B virus vaccine, and has a better application prospect in prevention of the encephalitis B virus infection.

Description

technical field [0001] The invention relates to a recombinant Japanese encephalitis virus and its application, in particular to a methyltransferase-deficient Japanese encephalitis virus and its application. Background technique [0002] Japanese encephalitis virus, also known as Japanese encephalitis virus, belongs to the Flavivirus genus of the family Flaviviridae. It is mainly transmitted by Culex mosquito bites and can cause severe encephalitis and neurological diseases clinically. Japanese encephalitis is mainly prevalent in Southeast Asia, the fatality rate is as high as 30%, and about 30-50% of patients leave serious sequelae. According to the estimates of the World Health Organization, there are more than 16,000 Japanese encephalitis patients and more than 5,000 deaths in Asia every year, posing a serious threat to human health and public health. Moreover, Japanese encephalitis has spread to other regions in recent years, such as Pakistan, Australia and other countri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/18C12N15/40C12N15/63C12N5/10C12N7/01C12N1/21A61K39/12A61P31/14C12N15/10C12R1/93
CPCY02A50/30
Inventor 秦成峰史佩勇李世华李晓峰赵慧秦鄂德
Owner MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com